The launch of Heme Libra, a 28-day hemophilia treatment, revealed a key challenge: patients accustomed to daily infusions were scared to trust the new, infrequent therapy. This shows that marketing truly disruptive products requires building trust and overcoming ingrained user habits, going beyond just demonstrating clinical superiority.

Contrary to the belief that great products sell themselves, truly transformative ideas require more marketing, not less. This is because they demand significant behavioral change, and marketing must provide the psychological reassurance for consumers to overcome the hurdle of adoption.

While you cannot promote a MedTech product before regulatory approval, you can and should promote the problem it solves. This 'problem marketing' strategy rewires the audience's thinking, making them feel the pain of the status quo. By the time your product launches, the market is already primed to seek your solution.

When introducing a disruptive model, potential partners are hesitant to be the first adopter due to perceived risk. The strategy is to start with small, persistent efforts, normalizing the behavior until the advantages become undeniable. Innovation requires a patient strategy to overcome initial industry inertia.

MedTech's data-driven culture fosters a false belief that strong clinical data is sufficient to drive adoption. In reality, all humans—including surgeons—make decisions emotionally first. Data's primary role is not to create initial belief but to provide rational validation for a change the market has already been primed to make.

In healthcare, the user, recommender, and payer are often different entities. A clinically effective product can easily fail if it's not inserted into the right point in the value chain where a stakeholder is both willing and incentivized to pay for it.

Early-stage MedTech companies often have a limited, narrow understanding of their market size and product-market fit. Their intense focus on product development and regulatory hurdles causes them to neglect crucial commercialization planning, creating a major strategy gap post-approval.

Disruptive MedTech ideas attract investment, but they are high-risk. Founders should de-risk these big bets by developing market access and commercial strategies simultaneously with product development, not after FDA approval.

Even after proving a device works, getting FDA clearance, and securing a reimbursement code, investors' final question is about market traction. They want to see revenue before funding the sales team required to generate it, creating a final catch-22.